Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> MutationRichard M. Stone, Hartmut Döhner, Sumithra J. Mandrekar et al.|New England Journal of Medicine|2017Cited by 2.2k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic LeukemiaFrancesco Lo‐Coco, Uwe Platzbecker, Giuseppe Avvisati et al.|New England Journal of Medicine|2013Cited by 1.6k
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working PartyGerrit Jan Schuurhuis, Gert J. Ossenkoppele, Brent L. Wood et al.|Blood|2018Cited by 1k
Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML)Christian Thiede|Blood|2006Cited by 726
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working PartyMichael Heuser, Jacqueline Cloos, Sylvie Freeman et al.|Blood|2021Cited by 714